里程碑系列：肝门部胆管癌。
The Landmark Series: Hilar Cholangiocarcinoma.
机构信息
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Surgery, Weill Cornell Medical College, New York, NY, USA.
出版信息
Ann Surg Oncol. 2021 Aug;28(8):4158-4170. doi: 10.1245/s10434-021-09871-6. Epub 2021 Apr 7.
Abstract
Hilar cholangiocarcinoma (HC) is a rare and highly aggressive biliary tract neoplasm. As such, the data driving the management of this disease generally are not based on prospective clinical trial data but rather consist of retrospective experiences and limited level 1 data. Surgical resection offers the best chance of a long-term survival, but local and distant recurrences are common. This report presents landmark articles that form the basis of preoperative, operative, and adjuvant strategies for HC.
摘要
肝门部胆管癌（HC）是一种罕见且高度侵袭性的胆道肿瘤。因此，指导该病管理的数据通常不是基于前瞻性临床试验数据，而是回顾性经验和有限的 1 级数据。手术切除是获得长期生存的最佳机会，但局部和远处复发很常见。本报告介绍了构成 HC 术前、术中和辅助治疗策略基础的重要文章。
相似文献
1
The Landmark Series: Hilar Cholangiocarcinoma.里程碑系列：肝门部胆管癌。
Ann Surg Oncol. 2021 Aug;28(8):4158-4170. doi: 10.1245/s10434-021-09871-6. Epub 2021 Apr 7.
2
Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma involving the hepatic hilus versus hilar cholangiocarcinoma after curative-intent resection: Should they be recognized as perihilar cholangiocarcinoma or differentiated?肝门部胆管癌累及肝门部与肝门部胆管癌根治性切除术后的长期预后和预后因素：是否应将其视为肝门周围胆管癌或加以区分？
Eur J Surg Oncol. 2019 Nov;45(11):2173-2179. doi: 10.1016/j.ejso.2019.06.014. Epub 2019 Jun 11.
3
Evolution of surgery for Klatskin tumor demonstrates improved outcome: a single center analysis.肝门部胆管癌手术的进展显示预后改善：一项单中心分析
Tumori. 2014 Nov-Dec;100(6):e250-6. doi: 10.1700/1778.19288.
4
[Radical surgery for hilar cholangiocarcinoma (Klatskin tumor)].肝门部胆管癌（克氏瘤）的根治性手术
Cir Esp. 2007 Jul;82(1):11-5. doi: 10.1016/s0009-739x(07)71654-8.
5
How to Determine Unresectability in Hilar Cholangiocarcinoma.如何判定肝门部胆管癌的不可切除性
Surg Clin North Am. 2024 Feb;104(1):197-214. doi: 10.1016/j.suc.2023.09.001. Epub 2023 Sep 27.
6
When Should Hepatectomy be Performed for the Treatment of Bismuth Type I and II Hilar Cholangiocarcinoma?治疗Bismuth I型和II型肝门部胆管癌时应何时进行肝切除术？
Ann Surg Oncol. 2020 Dec;27(Suppl 3):926-927. doi: 10.1245/s10434-020-08560-0. Epub 2020 May 11.
7
[Surgical therapy of hilar cholangiocarcinoma].[肝门部胆管癌的外科治疗]
Chirurg. 2006 Apr;77(4):325-34. doi: 10.1007/s00104-006-1177-4.
8
The effect of secondary resection for patients with primary positive ductal margin of hilar cholangiocarcinoma: An updated meta-analysis.肝门部胆管癌原发性切缘阳性患者二次切除的效果：一项更新的荟萃分析。
Asian J Surg. 2022 Sep;45(9):1780-1782. doi: 10.1016/j.asjsur.2022.03.098. Epub 2022 Apr 11.
9
Current therapy of hilar cholangiocarcinoma.肝门部胆管癌的当前治疗方法。
Hepatobiliary Pancreat Dis Int. 2012 Feb;11(1):12-7. doi: 10.1016/s1499-3872(11)60119-7.
10
Reply to: "When Should Hepatectomy be Performed for the Treatment of Bismuth Type I and II Hilar Cholangiocarcinoma?".回复：“治疗Bismuth I型和II型肝门部胆管癌时何时应进行肝切除术？”
Ann Surg Oncol. 2020 Dec;27(Suppl 3):928-929. doi: 10.1245/s10434-020-08562-y. Epub 2020 Jun 16.
引用本文的文献
1
Comparison of prognostic factors and their differences in intrahepatic, hilar, and distal cholangiocarcinoma: A systematic review and meta-analysis.肝内、肝门部和肝外胆管癌预后因素及其差异的比较：一项系统评价和荟萃分析。
World J Gastrointest Oncol. 2025 Jul 15;17(7):107995. doi: 10.4251/wjgo.v17.i7.107995.
2
Hilar cholangiocarcinoma patients accepting preoperative percutaneous transhepatic biliary drainage experienced high incidence of portal vein invasion and lymph node metastasis.接受术前经皮经肝胆道引流的肝门部胆管癌患者门静脉侵犯和淋巴结转移发生率较高。
Front Oncol. 2025 Jun 6;15:1504604. doi: 10.3389/fonc.2025.1504604. eCollection 2025.
3
Does caudate lobe resection really improve the surgical outcomes of patients with hilar cholangiocarcinoma? A multicenter retrospective study.尾状叶切除术真的能改善肝门部胆管癌患者的手术疗效吗？一项多中心回顾性研究。
Sci China Life Sci. 2025 Mar 27. doi: 10.1007/s11427-024-2855-x.
4
Biliary metallic stent combined with radioactive 125I seeds strands for malignant hilar obstruction.胆道金属支架联合放射性125I粒子链治疗恶性肝门部梗阻
BMC Cancer. 2025 Feb 10;25(1):229. doi: 10.1186/s12885-025-13627-w.
5
Endoscopic Stenting of a Fully Covered Self-Expandable Metal Stent with a Hole in Each Cavity in Malignant Hilar Biliary Obstruction: A Preclinical Proof-of-Concept Study and Initial Human Experience.用于恶性肝门部胆管梗阻的每个腔内有孔的全覆膜自膨式金属支架的内镜下置入：一项临床前概念验证研究及初步人体经验
Dig Dis Sci. 2025 Mar;70(3):1215-1222. doi: 10.1007/s10620-024-08810-1. Epub 2025 Jan 24.
6
Screening and molecular mechanism research on bile microRNAs associated with chemotherapy efficacy in perihilar cholangiocarcinoma.肝门部胆管癌化疗疗效相关胆汁微小RNA的筛选及分子机制研究
iScience. 2024 Dec 4;27(12):111437. doi: 10.1016/j.isci.2024.111437. eCollection 2024 Dec 20.
7
Body composition as a prognostic factor in cholangiocarcinoma: a meta-analysis.体成分分析作为胆管癌预后因素的研究：一项荟萃分析。
Nutr J. 2024 Nov 15;23(1):145. doi: 10.1186/s12937-024-01037-w.
8
"Hepatic hilum area priority, liver posterior first": An optimized strategy in laparoscopic resection for type III-IV hilar cholangiocarcinoma.“肝门区优先，肝后叶先行”：Ⅲ-Ⅳ型肝门部胆管癌腹腔镜切除术的优化策略
World J Gastrointest Surg. 2024 Jul 27;16(7):2167-2174. doi: 10.4240/wjgs.v16.i7.2167.
9
Dynamic three-dimensional liver volume assessment of liver regeneration in hilar cholangiocarcinoma patients undergoing hemi-hepatectomy.肝门部胆管癌患者半肝切除术后肝再生的动态三维肝脏体积评估
Front Oncol. 2024 Apr 19;14:1375648. doi: 10.3389/fonc.2024.1375648. eCollection 2024.
10
Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches.胆管癌：分子病理生物学与治疗方法的最新进展
Cancers (Basel). 2024 Feb 16;16(4):801. doi: 10.3390/cancers16040801.
本文引用的文献
1
Combined Vascular Resection for Locally Advanced Perihilar Cholangiocarcinoma.联合血管切除治疗局部进展期肝门部胆管癌
Ann Surg. 2022 Feb 1;275(2):382-390. doi: 10.1097/SLA.0000000000004322.
2
Defining the optimal bilirubin level before hepatectomy for hilar cholangiocarcinoma.定义肝门部胆管癌肝切除术前的最佳胆红素水平。
BMC Cancer. 2020 Sep 23;20(1):914. doi: 10.1186/s12885-020-07385-0.
3
How long should follow-up be continued after R0 resection of perihilar cholangiocarcinoma?肝门部胆管癌 R0 切除术后应继续随访多长时间？
Surgery. 2020 Oct;168(4):617-624. doi: 10.1016/j.surg.2020.04.068. Epub 2020 Jul 19.
4
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.胆管癌 2020：机制和管理的新前沿。
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
5
Surgical Considerations of Hilar Cholangiocarcinoma.肝门部胆管癌的手术考量
Surg Oncol Clin N Am. 2019 Oct;28(4):601-617. doi: 10.1016/j.soc.2019.06.003. Epub 2019 Aug 2.
6
A Study on Radial Margin Status in Resected Perihilar Cholangiocarcinoma.肝门周围胆管癌切缘状态的研究。
Ann Surg. 2021 Mar 1;273(3):572-578. doi: 10.1097/SLA.0000000000003305.
7
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.卡培他滨对比观察用于可切除胆管癌（BILCAP）：一项随机、对照、多中心、3 期研究。
Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25.
8
Clinical value of additional resection of a margin-positive distal bile duct in perihilar cholangiocarcinoma.肝门周围胆管癌切缘阳性的远端胆管附加切除的临床价值。
Br J Surg. 2019 May;106(6):774-782. doi: 10.1002/bjs.11125. Epub 2019 Mar 19.
9
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.胆道癌切除术后辅助治疗：ASCO 临床实践指南。
J Clin Oncol. 2019 Apr 20;37(12):1015-1027. doi: 10.1200/JCO.18.02178. Epub 2019 Mar 11.
10
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.吉西他滨和奥沙利铂化疗或监测在切除的胆管癌 (PRODIGE 12-ACCORD 18-UNICANCER GI)：一项随机 III 期研究。
J Clin Oncol. 2019 Mar 10;37(8):658-667. doi: 10.1200/JCO.18.00050. Epub 2019 Feb 1.
Zotero 插件